RANI THERAPEUTICS HOLDINGS-A (RANI)
US7530181004 - Common Stock
Overall RANI gets a fundamental rating of 1 out of 10. We evaluated RANI against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of RANI have multiple concerns. RANI has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
RANI had negative earnings in the past year.
In the past year RANI has reported a negative cash flow from operations.
In the past 5 years RANI always reported negative net income.
RANI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
RANI has a Return On Assets of -64.70%. This is in the lower half of the industry: RANI underperforms 69.11% of its industry peers.
Looking at the Return On Equity, with a value of -902.85%, RANI is doing worse than 83.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.7% | ||
| ROE | -902.85% | ||
| ROIC | N/A |
ROA(3y)-31.23%
ROA(5y)-46.07%
ROE(3y)-121.5%
ROE(5y)-105.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for RANI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, RANI has less shares outstanding
RANI has a worse debt/assets ratio than last year.
2.2 Solvency
RANI has an Altman-Z score of -5.42. This is a bad value and indicates that RANI is not financially healthy and even has some risk of bankruptcy.
RANI has a Altman-Z score of -5.42. This is in the lower half of the industry: RANI underperforms 65.44% of its industry peers.
RANI has a Debt/Equity ratio of 4.34. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of RANI (4.34) is worse than 85.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.34 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.42 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
RANI has a Current Ratio of 1.60. This is a normal value and indicates that RANI is financially healthy and should not expect problems in meeting its short term obligations.
RANI has a worse Current ratio (1.60) than 68.06% of its industry peers.
A Quick Ratio of 1.60 indicates that RANI should not have too much problems paying its short term obligations.
RANI has a Quick ratio of 1.60. This is in the lower half of the industry: RANI underperforms 61.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.6 | ||
| Quick Ratio | 1.6 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 24.82% over the past year.
EPS 1Y (TTM)24.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
RANI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.11% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y23.5%
EPS Next 2Y12.08%
EPS Next 3Y13.48%
EPS Next 5Y11.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RANI. In the last year negative earnings were reported.
Also next year RANI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as RANI's earnings are expected to grow with 13.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.08%
EPS Next 3Y13.48%
5. Dividend
5.1 Amount
No dividends for RANI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
RANI THERAPEUTICS HOLDINGS-A
NASDAQ:RANI (12/20/2024, 8:00:01 PM)
After market: 1.4199 +0.02 (+1.42%)1.4
+0.1 (+7.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners10.06%
Inst Owner Change96.8%
Ins Owners2.15%
Ins Owner Change0.71%
Market Cap80.21M
Analysts85.71
Price Target11.73 (737.86%)
Short Float %6.32%
Short Ratio0.66
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.09%
Min EPS beat(2)8.92%
Max EPS beat(2)19.26%
EPS beat(4)3
Avg EPS beat(4)0.85%
Min EPS beat(4)-39.83%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)5.04%
EPS beat(12)11
Avg EPS beat(12)18.5%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.13%
PT rev (3m)-2.13%
EPS NQ rev (1m)10.56%
EPS NQ rev (3m)-0.84%
EPS NY rev (1m)-1.79%
EPS NY rev (3m)-1.79%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 25.71 | ||
| P/tB | 25.71 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.06
EYN/A
EPS(NY)-0.99
Fwd EYN/A
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS0
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.7% | ||
| ROE | -902.85% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-31.23%
ROA(5y)-46.07%
ROE(3y)-121.5%
ROE(5y)-105.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.34 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 41.26% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.6 | ||
| Quick Ratio | 1.6 | ||
| Altman-Z | -5.42 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)182.02%
Cap/Depr(5y)206.32%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y23.5%
EPS Next 2Y12.08%
EPS Next 3Y13.48%
EPS Next 5Y11.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.01%
EBIT Next 3Y4.89%
EBIT Next 5Y8.36%
FCF growth 1Y11.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.28%
OCF growth 3YN/A
OCF growth 5YN/A